Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

141.54 +0.08 (+0.06%)

Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

53 54 Next >

Relay Therapeutics' Stock Price Premium Vs Peers Is Justified By Its Platform Technology, Analyst Says ↗

April 13, 2023

Via Benzinga

Novartis Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗

April 13, 2023

Via Benzinga

Alzheimer's Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments — Could Regulatory T-Cells (Tregs) Be The Answer? ↗

April 13, 2023

In many ways, Alzheimer's disease (AD) remains a mystery. Most common in those over 65, AD is the most common form of dementia, but its exact causes remain unclear, and treatments are unable to halt or...

Via Benzinga

Trillions In Biotech Stock Gains Trace Back To This Financier ↗

April 13, 2023

Frank did not grow up as son of a Wall Street banker. He began as the consummate outsider.

Via Investor's Business Daily

Epic Growth Story Predicted for Pharmaceutical Drug Delivery Market's Future: Johnson & Johnson, Novartis International, Merck

April 12, 2023

Stay up-to-date with Pharmaceutical Drug Delivery Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth.

Via SBWire

Novartis AG (NYSE: NVS) Records 52-Week High Thursday Morning

April 06, 2023

Via Investor Brand Network

FDA Approves Pharming's Immune Disorder Drug, As First APDS Therapy ↗

March 27, 2023

Via Benzinga

How Is The Market Feeling About Novartis? ↗

March 21, 2023

Via Benzinga

Tilray Brands Consolidates Hold: Profits Will Drive Shares Higher

April 12, 2023

Tilray Brands moves lower on mixed results, but the bottom may be in, with positive FCF expected this quarter. The long-term catalyst is US legalization.

Via MarketBeat

Topics Cannabis

Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move ↗

April 10, 2023

Via Benzinga

Top-Notch Biotech TG Therapeutics Logs 'Solid Jump' In Sales; Shares Rocket ↗

April 10, 2023

Shares are closing in on a buy point out of a consolidation.

Via Investor's Business Daily

Pediatric Drugs Market Giants Spending Is Going to Boom : Pfizer, Bayer, Abbott Laboratories, Merck

April 10, 2023

NJ New Jersey, USA -- (SBWIRE) -- 04/10/2023 -- Latest Study on Industrial Growth of Pediatric Drugs Market 2022-2027. A detailed study accumulated to offer Latest insights about acute features of the...

Via SBWire

FDA Approves Novartis' Tafinlar + Mekinist For Pediatric Brain Cancer With Certain Mutations ↗

March 17, 2023

Via Benzinga

Cryoport Supports Clinical Trials And Commercial Therapies Across The High-Growth BioTech Industry: Is Its Current Stock Price An Opportunity? ↗

April 10, 2023

The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.

Via Benzinga

Novartis Shares Leap On Positive Clinical Trial Data

April 10, 2023

Swiss pharmaceutical giant Novartis leaped 5.11% in the past week following news that its Kisqali breast-cancer treatment cut the probability of relapse.

Via MarketBeat

6 Questions With Rocket Pharma's CEO On World Health Day: How The Biotech Is 'Changing The Narrative' ↗

April 07, 2023

Rocket Pharma (NASDAQ: RCKT) CEO Gaurav Shah is on a mission to "change the narrative" when it comes to rare diseases.

Via Benzinga

7 Very Undervalued Penny Stocks to Buy in April 2023 ↗

April 06, 2023

Undervalued penny stocks present investors who are very bullish on the near-term future with a high-risk, high-reward option.

Via InvestorPlace

The Byzantine Adderall Shortage Puts Teva And Others In The Hot Seat ↗

April 05, 2023

Millions of people are scrambling to get their ADHD medication. Here's why.

Via Investor's Business Daily

Stock Market Rallies On Micron, Alibaba, Lululemon, Ebbing Bank Fears: Weekly Review ↗

March 31, 2023

The stock market rallied on ebbing bank fears and positive news from Micron, Alibaba and Lululemon Athletica.

Via Investor's Business Daily

What Bear Market? These 2 Winning Stocks Are Still Worth Buying. ↗

March 30, 2023

These two pharma stocks are rock-solid picks in any kind of market.

Via The Motley Fool

Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 27, 2023

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider.

Via Benzinga

Elon Musk-Led Neuralink Seeks Human Trial Collaborators, Credit Suisse May Face Disciplinary Action, First Citizens Takeover Silicon Valley Bank: Today's Top Stories ↗

March 27, 2023

Benzinga

Via Benzinga

Novartis Surges As It Goes After Eli Lilly's Second Biggest Moneymaker ↗

March 27, 2023

The battle in early-stage breast cancer is heating up as Novartis enters the ring.

Via Investor's Business Daily

Why Novartis Shares Are Trading Higher Premarket Today ↗

March 27, 2023

Novartis AG (NYSE: NVS) shares are trading higher in the premarket session after its breast cancer drug showed clinical benefit in early-stage breast cancer.

Via Benzinga

First Republic Bank, KeyCorp And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

March 27, 2023

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

New research project aims to set standardized approach to lipoprotein(a) management

March 24, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

2 Biotech Stocks That Could Make You Richer ↗

March 21, 2023

One is a well-established, large-cap drugmaker, while the other is still making a name for itself in the industry.

Via The Motley Fool

Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo ↗

March 20, 2023

Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days.

Via Benzinga

Novartis Reveals Long-Term Data Of Atrophy Gene Therapy Exhibiting Sustained Durability Of Up To 7.5 Years ↗

March 20, 2023

Via Benzinga

Elon Musk Frets As Microsoft Axes AI Ethics Team, Richard Branson's Virgin Orbit Stops Ops, Credit Suisse To Borrow Up To $54B: Today's Top Stories ↗

March 16, 2023

Benzinga

Via Benzinga

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

53 54 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

All News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today